Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 23

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Subarachnoid haemorrhage

Recruiting

Study on the Safety and Effectiveness of Parecoxib and Sodium Chloride for Patients Hospitalized with Spontaneous Subarachnoid Hemorrhage

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:PARECOXIB
  • Sponsor:Fakultni Nemocnice U Sv Anny V Brne

Tuberous sclerosis complex+1

Recruiting

Study on the Safety and Effectiveness of Sirolimus and Vigabatrin for Preventing Symptoms in Infants with Tuberous Sclerosis Complex

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Sirolimus
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Anal incontinence

Recruiting

Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ICEF15
  • Sponsor:Innovacell GmbH

Parkinson's disease

Recruiting

Study of apomorphine and rifaximin for Parkinson's disease patients with reduced levodopa effectiveness

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Domperidone
  • Sponsor:Stichting Radboud University Medical Center

Glioblastoma

Recruiting

Study of Itraconazole with Radiotherapy and Temozolomide for Patients with Newly Diagnosed Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itraconazole
  • Sponsor:Otto Von Guericke Universitaet Magdeburg

Neuralgia+1

Recruiting

Study on Psilocybin for Relieving Chronic Neuropathic Pain in Patients with Chemotherapy-Induced Peripheral Neuropathy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxazepam
  • Sponsor:Amsterdam UMC Stichting

Tuberous sclerosis complex+1

Recruiting

Study on the Effectiveness and Safety of Sirolimus for Patients with Drug-Resistant Epilepsy Linked to Tuberous Sclerosis Complex

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Sirolimus
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Glioblastoma

Recruiting

Study on the Use of Metformin in Addition to Standard Treatment for Patients with Glioblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Brain stem glioma

Recruiting

Study on the Effectiveness of Sirolimus and Trametinib for Treating Diffuse Intrinsic Pontine Glioma in Children Aged 3-18 Years

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Sirolimus
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Rett syndrome

Recruiting

Study on the Effects of Mirtazapine for Improving Symptoms in Patients with Rett Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Mirtazapine
  • Sponsor:University Of Trieste

Cognitive disorder+1

Recruiting

Study on the Safety and Effects of NTRX-07 for Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer's Disease

Investigational
Countries:CzechiaCzechia
  • Participants:65+ years
  • Substances:(3-BENZYL-3-METHYL-2,3-DIHYDROBENZOFURAN-6- YL)(PIPERIDIN-1-YL)METHANONE
  • Sponsor:Neurotherapia Inc.

Basal cell naevus syndrome

Recruiting

Study of Sonidegib for Patients with Nevoid Basal Cell Carcinoma Syndrome and Sporadic Basal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sonidegib
  • Sponsor:Fondazione GONO Plus

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.